Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Concentrative nucleoside transporter 3 (hCNT3, encoded by *SLC28A3*) is a plasma membrane protein of the solute carrier family, functioning primarily as a sodium-dependent nucleoside transporter capable of importing both physiological nucleosides and a broad range of nucleoside analog therapeutic agents—including anti-cancer and antiviral drugs—into cells[1][2][3][5][7]. hCNT3 is structurally characterized by a homo-trimeric assembly and is broadly expressed in human tissues, particularly in the kidney and epithelia[1][3][4]. Its broad substrate selectivity and pivotal transport role render it a key determinant of tissue disposition and pharmacological efficacy of nucleoside analog drugs. Genetic variants in *SLC28A3* can modulate function and expression, impacting drug response and toxicity[7].
Facilitates sodium-dependent cellular uptake of nucleosides and nucleoside analog drugs, enabling their cytotoxic or antiviral activity by permitting intracellular accumulation[2][3][7].
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Concentrative nucleoside transporter 3 (hCNT3).